|
Chỉ định và Liều dùng
Oral
Traveller's diarrhoea caused by non-invasive strains of E. coli Adult: As rifamycin base (194 mg rifamycin is equivalent to 200 mg rifamycin sodium): 388 mg bid for 3 days. If symptoms worsen or persist >48 hours, discontinue treatment and consider alternative antibacterial agent.
|
|
Các sản phẩm có chứa hoạt chất Rifamycin tại Việt Nam?
|
|
Chống chỉ định
Hypersensitivity to rifamycin or any rifamycin class antibiotic (e.g. rifampicin, rifabutin, rifaximin).
|
|
Thận trọng
Patient with gastrointestinal obstructions or perforations, severe intestinal ulcerative lesions. Not indicated for the treatment of diarrhoea complicated by fever or bloody stool, or due to pathogens other than non-invasive strains of Escherichia coli. Renal and hepatic impairment. Pregnancy and lactation.
|
|
Tác dụng không mong muốn
Significant: Bacterial superinfection including Clostridium difficile-associated diarrhoea (prolonged use), reddish discolouration of the urine.
Gastrointestinal disorders: Abdominal pain, constipation, dyspepsia. General disorders and administration site conditions: Fever. Nervous system disorders: Headache. |
|
Chỉ số theo dõi
Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor the frequency of diarrhoea. Observe for bloody stools.
|
|
Tương tác
May increase the risk of severe disruption of gastrointestinal microbiota when given with other rifamycin class antibiotics; avoid concomitant use.
|
|
Tác dụng
Description:
Mechanism of Action: Rifamycin, an antibacterial agent, irreversibly blocks the β-subunit of the bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase, thus inhibiting bacterial RNA synthesis and consequently bacterial growth. It is locally acting in the intestinal lumen due to its very low absorption from the gastrointestinal tract, therefore it is not clinically effective against invasive enteritis. Pharmacokinetics: Absorption: Bioavailability: <0.1% (fasted state). Distribution: Plasma protein binding: Approx 80%, mainly to albumin. Excretion: Via faeces (86%). Elimination half-life: Approx 1 hour. |
|
Đặc tính
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 6324616, Rifamycin. https://pubchem.ncbi.nlm.nih.gov/compound/Rifamycin. Accessed May 30, 2022. |
|
Bảo quản
Store between 15-30°C.
|
|
Phân loại MIMS
|
|
Phân loại ATC
A07AA13 - rifamycin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
|
|
Tài liệu tham khảo
Aemcolo Tablet, Delayed Release (Aries Pharmaceuticals Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 02/03/2022. Anon. Rifamycin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/03/2022. Anon. Rifamycin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/03/2022. Buckingham R (ed). Rifamycin Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/03/2022. Relafalk 200 mg Modified-release Tablets (Dr Falk Pharma GmbH). MHRA. https://products.mhra.gov.uk. Accessed 02/03/2022.
|
Đăng xuất
